Exelixis
Trade Exelixis 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About EXEL
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic.
EXEL Key Statistics
Stock Snapshot
The current Exelixis(EXEL) stock price is $44.19, with a market capitalization of 11.83B. The stock trades at a price-to-earnings (P/E) ratio of 18.54.
During the trading session on 2026-01-13, Exelixis(EXEL) shares reached a daily high of $45.06 and a low of $41.51. At a current price of $44.19, the stock is +6.5% higher than the low and still -1.9% under the high.
Trading activity shows a volume of 4.14M, compared to an average daily volume of 2.54M.
Over the past 52 weeks, Exelixis(EXEL) stock has traded between a high of $49.62 and a low of $31.90.
Over the past 52 weeks, Exelixis(EXEL) stock has traded between a high of $49.62 and a low of $31.90.
EXEL News
U.S. stock futures were lower this morning, with the Dow futures falling more than 300 points on Monday. Shares of Exelixis Inc (NASDAQ:EXEL) fell sharply in p...
“Exelixis (EXEL) enters 2026 with a strong and growing commercial business, the opportunity to bring a potential second oncology franchise to market and an exci...
Exelixis (EXEL) is back in focus after reporting strong phase 3 data for zanzalintinib in metastatic colorectal cancer, alongside launching the Natera partnersh...
Analyst ratings
50%
of 22 ratingsMore EXEL News
Wondering if Exelixis at a last close of US$46.19 still offers value, or if the easy money has already been made? This article walks through what the numbers ar...
Exelixis recently announced that President and CEO Michael M. Morrissey, Ph.D., had provided a corporate overview at the J.P. Morgan 2026 Healthcare Conference,...